Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.

Semiconductor-Based Nanopore Sequencing Platform Developed for Molecular Diagnostics

By Labmedica International staff writers
Posted on 24 Jan 2012
A startup company is developing a semiconductor-based nanopore-sequencing platform that will be used for molecular diagnostic applications.

Genia, the Mountain View (CA, USA)-based startup has an alpha version of its single-molecule platform in hand and is currently optimizing the biochemistry for a beta system.

Stefan Roever, CEO and founder of the company declined to provide a commercialization timeline for the system or details regarding expected read length or accuracy, but noted that he believes the platform will be able to sequence genomes at a cost "one order of magnitude less" than other single-molecule systems.

He described the system as a "single-molecule electrical detection sequencing platform," and said that the company expects it to be useful for targeted resequencing and molecular diagnostics that involve both human genomics and viral or bacterial DNA.

A number of other firms are developing nanopore sequencing systems, but Stephen Roever said that Genia's focus on the underlying chip platform sets it apart from competitors.

"We focused on operationalizing the nanopores," Stephen Roever said. "We essentially developed a way to create what are effectively lipid bilayer nanopore complexes, so the biological nanopore is a transmembrane protein that's suspended in a lipid bilayer."

The company has developed a way to "automatically set up whole arrays of [the nanopores] on the surface of a semiconductor chip and integrated circuit," ultimately making a "very complicated" process "massively scalable."

"We have a working platform and chip, and we have the basic building blocks on the biochemistry side. The next step is to take those and assemble them into a robust chemistry," said Mr. Roever. "That's where the focus is going to be and there's a significant amount of work still to be done there."

Related Links:

Genia



CELLAVISION AB
MEDLAB Asia
KARL HECHT GMBH & CO KG

Channels

Industry News

view channel
Image: Positive case of lung tissue stained for ALK with VENTANA ALK (D5F3) CDx Assay, a companion diagnostic immunohistochemical test in the final stages of the FDA premarket approval process (Photo courtesy of Ventana Medical Systems and PRNewsFoto).

Premarket Approval Sought for CDx Test to Benefit Lung Cancer Patients

Ventana Medical Systems, Inc. (Tucson, AZ, USA) has announced its US Food & Drug Administration (FDA) final stage submission for premarket approval (PMA) of its companion diagnostic (CDx) immunohistochemistry... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.